Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

How the Development Bank of Wales supports tech-driven companies, ranging from start-ups to established businesses ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning, and welcome to Fluor’s Third Quarter 2024 Earnings ...

With the rise of exchange-traded funds, or ETFs, that let you buy and sell throughout the trading day, mutual funds have fallen out of the limelight. But don't write off the old stalwart of ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

In July, our management team was strengthened with the addition of ... working at companies such as Roche, The Medicines Company, Eli Lilly, Pfizer and Johnson & Johnson. It is worth pointing out that ...

This could bring positive returns, helped by the macroeconomic environment, the potential for improvement in corporate earnings and the increased use of buybacks by European management teams ...

Eli Lilly, and Berkshire Hathaway. Given these factors, Canadian investors can consider adding Vanguard S&P 500 Index ETF ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...